Flash Finance

Alkem Laboratories LimitedALKEMCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹5,050.00
MCap ₹60,380 Cr · P/E 27.3
Alkem Laboratories Limited — Stock analysis & AI research Alkem Laboratories Limited — Multibagger AI analysis Alkem Laboratories Limited — Seasonality — best & worst months Alkem Laboratories Limited — Technical indicators & charts Alkem Laboratories Limited — Technical setup — score, trend, support & resistance Alkem Laboratories Limited — Triple Top pattern broken down ↓ Alkem Laboratories Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Interest Coverage Stocks📋 GARP Stocks (PEG Below 1)📋 Low Debt Stocks📋 Mid Cap Stocks List📋 Quality Stocks 📈 MACD Bearish Crossover📈 New 52-Week Low Stocks📈 20-Day Breakdown Stocks📈 Lowest Technical Score📈 Multi-Timeframe Bearish Stocks📈 Stocks Near 52-Week Low 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹2,668 Cr
Sales · Jun 2026
+12.5% YoY
₹737 Cr
Operating Profit · Jun 2026
+18.8% YoY
27.6%
OPM % · Jun 2026
+5.7% YoY
₹570 Cr
Net Profit · Jun 2026
-13.1% YoY
₹47.67
EPS · Jun 2026
-13.1% YoY

📝 Alkem Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Alkem Laboratories Limited reported revenue of ₹2,668 crore for the quarter ended June 2026 (Q1 FY27), up 12.5% from ₹2,372 crore in the same quarter last year, and up 18.1% sequentially over the March 2026 quarter.

Net profit fell 13.1% year-on-year to ₹570 crore, from ₹656 crore. Earnings per share (EPS) came in at ₹47.67.

Operating profit stood at ₹737 crore — an operating margin (OPM) of 27.6%, compared with 26.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Alkem Laboratories Limited posted revenue of ₹10,909 crore, a decline of 9.5% over FY25, with a net profit of ₹2,296 crore (up 4.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹11,205 crore with a net profit of ₹2,210 crore.

Valuation snapshot

At the current price of ₹5,050.00, ALKEM has a market capitalisation of ₹60,380 crore and a trailing P/E of about 27.3.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 12th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 51.20%, foreign institutional investors (FIIs) 10.15%, domestic institutional investors (DIIs) 21.39%, public shareholders 17.25% of Alkem Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹60,380 Cr
Current Price ?
₹5,050.0
P/E ?
27.32below ind
Industry P/E ?
35.00
P/B ?
4.31
P/S ?
5.39
P/FCF ?
33.14
Enterprise Value ?
₹60,991 Cr
EV/EBITDA ?
22.76
PEG ?
1.05
Earnings Yield ?
4.0%
Dividend Yield ?
0.89%
Profitability & Returns
Sales (TTM) ?
₹11,205 Cr
OPM ?
23.9%
Profit after tax (TTM) ?
₹2,210 Cr
EPS (TTM) ?
₹184.81
ROCE ?
20.0%
ROE ?
15.8%
ROA ?
12.8%
Growth
Sales — latest qtr ?
₹2,668 Cr
PAT — latest qtr ?
₹570 Cr
YoY qtr sales growth ?
12.5%
YoY qtr profit growth ?
-13.1%
Sales growth (3y) ?
2%
Sales growth (5y) ?
6%
Profit growth (3y) ?
26%
Profit growth (5y) ?
7%
Financial Health
Debt ?
₹611 Cr
Debt to Equity ?
0.04
Interest Coverage ?
39.9
Current Ratio ?
N/A
Ownership
Promoter holding ?
51.20%
Change in promoter holding ?
-1.84%
Pledged percentage ?
N/A
Market
Return 3 months ?
-9.2%
Return 6 months ?
-9.5%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 3,0412,9032,2533,4403,3242,9362,1273,4153,3743,1442,3722,5423,7372,2582,668 +12.5% +18.1%
Operating Profit 599353334747708402561753759391620771828344737 +18.8% +114.1%
Other Income —77656293711441762161631651019386137 -17.2% +58.9%
Interest 232221192121211721171313161618 +34.8% +9.5%
Depreciation 585758595769636168925959617857 -3.0% -26.6%
Profit Before Tax 539212319648706380621780731396714898781336798 +11.8% +137.6%
Net Profit 45571271620595294583689626306656787636217570 -13.1% +162.7%
EPS 32.5321.3122.7054.0742.1727.1848.7858.3460.4823.1654.8865.8052.0318.1547.67 -13.1% +162.6%
OPM % 19.7% 12.2% 14.8% 21.7% 21.3% 13.7% 26.4% 22.0% 22.5% 12.4% 26.1% 30.3% 22.2% 15.2% 27.6% +5.7% +81.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹12,060 Cr ₹10,909 Cr ₹11,205 Cr -9.5%
Operating Profit ₹2,464 Cr ₹2,563 Cr ₹2,679 Cr +4.0%
OPM % 20.44% 23.49% 23.91% +14.9%
NPM % 18.27% 21.04% 19.72% +15.2%
Other Income ₹699 Cr ₹445 Cr ₹417 Cr -36.3%
Depreciation ₹284 Cr ₹257 Cr ₹255 Cr -9.7%
Interest ₹76 Cr ₹58 Cr ₹62 Cr -24.0%
EBIT ₹2,180 Cr ₹2,306 Cr ₹2,424 Cr +5.8%
PBT ₹2,529 Cr ₹2,729 Cr ₹2,813 Cr +7.9%
Tax — ₹111 Cr ₹339 Cr —
Net Profit ₹2,203 Cr ₹2,296 Cr ₹2,210 Cr +4.2%
EPS ₹190.76 ₹190.86 ₹183.65 +0.1%
Material Cost — ₹690 Cr ₹1,510 Cr —
Employee Cost — ₹461 Cr ₹1,008 Cr —
Extraordinary Items — ₹-53 Cr ₹-53 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 24242424 +0.0%
Reserves 9,32610,53112,29813,975 +13.6%
Borrowings 1,1821,005439611 +39.2%
Other Liabilities 2,2002,4782,8352,651 -6.5%
Total Liabilities 12,73114,03815,59617,261 +10.7%
Fixed Assets 1,8251,7821,5911,586 -0.3%
CWIP 229917686 +13.2%
Investments 3,0062,8294,4075,552 +26.0%
Other Assets 7,6729,3369,52110,037 +5.4%
Total Assets 12,73114,03815,59617,261 +10.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
CFO/OP 120%122%120%101% -15.8%
Cash from Operating Activity 1,4371,6872,1891,969 -10.1%
Cash from Investing Activity 197-866-1,007-1,461 -45.1%
Cash from Financing Activity -1,711-959-1,037-673 +35.1%
Net Cash Flow -77-138145-165 -213.8%
Free Cash Flow 1,2981,5862,0031,822 -9.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 71806559 -9.2%
Inventory Days 164257196212 +8.2%
Days Payable 103219188192 +2.1%
Cash Conversion Cycle 1331197279 +9.7%
Working Capital Days 50171128143 +11.7%
ROCE % 13%16%20%20% +0.0%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 53.04%51.20%51.20%51.20% +0.0%
FIIs 9.11%9.47%9.97%10.15% +1.8%
DIIs 21.80%21.93%21.54%21.39% -0.7%
Public 16.05%17.39%17.30%17.25% -0.3%
No. of Shareholders 79,74067,19664,53662,835 -2.6%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Alkem Laboratories Limited's revenue in Q1 FY27?
Alkem Laboratories Limited reported revenue of ₹2,668 crore for the quarter ended June 2026 (Q1 FY27), up 12.5% from ₹2,372 crore in the same quarter last year, and up 18.1% sequentially over the March 2026 quarter.
What was Alkem Laboratories Limited's net profit in Q1 FY27?
Net profit fell 13.1% year-on-year to ₹570 crore, from ₹656 crore. Earnings per share (EPS) came in at ₹47.67.
What is ALKEM's market capitalisation and P/E ratio?
At the current price of ₹5,050.00, ALKEM has a market capitalisation of ₹60,380 crore and a trailing P/E of about 27.3.
Who owns Alkem Laboratories Limited? (shareholding pattern)
As of Mar 2026, promoters held 51.20%, foreign institutional investors (FIIs) 10.15%, domestic institutional investors (DIIs) 21.39%, public shareholders 17.25% of Alkem Laboratories Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI